EMPOX - A Randomised, Double-blinded, Placebo Controlled Study That Evaluates the Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms EMPOX
- 09 Jun 2021 Status changed from active, no longer recruiting to completed.
- 24 Feb 2020 Status changed from recruiting to active, no longer recruiting.
- 01 Dec 2016 Status changed from not yet recruiting to recruiting.